Physician profile
Dawn Macke
NPI 1336512672
$3,982.57
in general payments reported to CMS, 2019-2025
24 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.83 · 2023: $633 · 2024: $1,430 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $815.24 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $448.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $283.56 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $267.07 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $166.74 | 2023-2025 | |
| Alkermes, INC. | $158.58 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Lundbeck LLC | $125.98 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $118.57 | 2024-2025 | Auvelity, Symbravo, Sunosi |
| Glaxosmithkline, LLC. | $79.37 | 2023-2025 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $75.44 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.99 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $52.41 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $35.73 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $34.74 | 2025 | Spravato |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.09 | 2025 | Jardiance |
| Currax Pharmaceuticals LLC | $30.20 | 2025 | Contrave |
| Neurocrine Biosciences, INC. | $23.19 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.61 | 2023 | Qelbree |
| Tandem Diabetes Care, INC. | $20.07 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $16.13 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $13.88 | 2025 | Jornay Pm |
| Abbott Laboratories | $13.19 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Macke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.